Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

QIM26-309: Use of Electronic Solution Supplemented With Portfolio of Tailored Resources Improves Tumor Response Assessment for Patients.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

QIM26-309: Use of Electronic Solution Supplemented With Portfolio of Tailored Resources Improves Tumor Response Assessment for Patients.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Phase I Randomized, Placebo-Controlled, Cross-Over Dose-Finding Study of Coenzyme Q10 on Doxorubicin Pharmacokinetics during Breast Cancer Treatment.

Integrative cancer therapies·2025
Same author

FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Regarding RECIST in retrospective studies.

The oncologist·2025
Same author

Comparing quantitative imaging biomarker alliance volumetric CT classifications with RECIST response categories.

Radiology advances·2025
Same journal

Corrigendum.

Anticancer research·2026
Same journal

Geographic Variation in Stage at Diagnosis of Skin Cancer in the United States: A National Cancer Database Analysis.

Anticancer research·2026
Same journal

Anti-tumor Effects of Loureirin A Treatment in Colorectal Cancer Cells <i>via</i> Inhibition of AKT Phosphorylation.

Anticancer research·2026
Same journal

Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab <i>vs</i>. Sunitinib) for Advanced Renal Cell Carcinoma.

Anticancer research·2026
Same journal

Pulsed Electromagnetic Field Increases Doxorubicin-induced Mitotic Slippage in MDA-MB-231 Breast Cancer Cells.

Anticancer research·2026
Same journal

Geographic Disparities in Socioeconomic Factors and Advanced-stage Presentation in Rectosigmoid Cancer: A National Cancer Database Analysis.

Anticancer research·2026
See all related articles

Related Experiment Video

Updated: May 18, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Gemcitabine-induced pulmonary toxicity.

Dow-Chung Chi1, Frances Brogan, Ithamar Turenne

  • 1Tufts Medical Center, Boston, MA 02111, USA.

Anticancer Research
|September 21, 2012
PubMed
Summary
This summary is machine-generated.

Gemcitabine, a pancreatic cancer drug, can cause rare but serious lung inflammation (pneumonitis). Early diagnosis and treatment are crucial to prevent potentially fatal outcomes in patients receiving this chemotherapy.

Related Experiment Videos

Last Updated: May 18, 2026

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Area of Science:

  • Oncology
  • Pulmonology
  • Pharmacology

Background:

  • Gemcitabine is a primary FDA-approved cytotoxic chemotherapy for pancreatic cancer.
  • It is also used for breast, ovarian, and non-small cell lung cancer.
  • While myelosuppression is common, gemcitabine-induced pulmonary toxicity, including pneumonitis, is rare (0.3%).

Observation:

  • A 56-year-old male with stage IV pancreatic cancer presented with dyspnea, chest tightness, and hypoxia (82-84% SpO2) during gemcitabine therapy.
  • Chest CT revealed new bilateral ground-glass opacities, indicative of pneumonitis.
  • Pulmonary embolism and myocardial infarction were excluded.

Findings:

  • The case highlights gemcitabine-induced pneumonitis as a rare adverse event.
  • This pulmonary toxicity can manifest as progressive dyspnea and hypoxia.

Implications:

  • Physicians must maintain a high index of suspicion for gemcitabine-induced pneumonitis in patients presenting with respiratory symptoms.
  • Prompt diagnosis and management are essential to mitigate potentially fatal outcomes associated with this rare chemotherapy complication.